Antibodies
Vinblastine
- 貨號 Cat. No.
- S1248
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
Vinblastine
Catalog No.S1248
Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.Phase 2.
| Size | Price | Stock | Quantity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Vinblastine does not interfere with phrenic nerve stimulation of rat diaphragm musculature in concentrations up to 200 microM. However, in relatively high doses, vinblastine (10-200 microM) produces an increase in baseline tension of diaphragm muscle. This effect is concentration related (EC50, approximately 88 microM), reversible, and independent of phrenic nerve stimulation. The elevation in baseline tension is unaffected by nAChR blockade via d-tubocurarine, but is dependent upon the presence of extracellular calcium. [1]
In human Burkitt lymphoma CA46 cells, vinblastine (IC50 values, 1.0 nM). [2]
It binds tubulin, thereby inhibiting the assembly of microtubules.It is used to treat certain kinds of cancer, including Hodgkin
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01887522 | Recruiting | Refractory Low-grade Gliomas|Recurrent Low-grade Gliomas | Gustave Roussy, Cancer Campus, Grand Paris|ITCC | 2013-05 | Phase 2 |
| NCT01884922 | Recruiting | Refractory Low-grade Gliomas|Recurrent Low-grade Gliomas | Gustave Roussy, Cancer Campus, Grand Paris | 2013-05 | Phase 1 |
| NCT01639521 | Withdrawn | Anterior Urethral Cancer|Localized Transitional Cell Cancer of the Renal Pelvis and Ureter|Posterior Urethral Cancer|Recurrent Bladder Cancer|Recurrent Urethral Cancer|Regional Transitional Cell Cance | USC/Norris Comprehensive Cancer Center|National Cancer Institute (NCI) | 2013-05 | Phase 2 |
| NCT01868451 | Recruiting | Hodgkin Lymphoma | Memorial Sloan-Kettering Cancer Center|Seattle Genetics, Inc. | 2013-05 | |
| NCT01684111 | Recruiting | Carcinoma, Non-Small-Cell Lung | Aktion Bronchialkarzinom e.V.|Boehringer Ingelheim Pharmaceuticals | 2013-06 | Phase 1 |
Chemical Information
| Molecular Weight (MW) | 810.97 |
|---|---|
| Formula | C46H58N4O9 |
| CAS No. | 865-21-4 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Vincaleukoblastine, Velban, Velsar |
| Solubility (25°C) * | In vitro | DMSO | 68 mg/mL (83 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | 6 mg/mL (7 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | 1H-Indolizino[8,1-cd]carbazole-5-carboxylic acid,4-(acetyloxy)-3a-ethyl-9-[5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-,methyl ester, [3aR-[3aa,4b,5b,5ab,9(3R*,5S*,7R*,9S*),10bR*,13aa]]- |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.82496 | 8.2496 | 16.4992 | 24.7488 |
